Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

Literature DB >> 23509307

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

Oliver Klein¹, Antoni Ribas, Bartosz Chmielowski, Grant Walker, Arthur Clements, Georgina V Long, Richard F Kefford.

Abstract

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2013 PMID： 23509307 DOI： 10.1200/JCO.2012.45.7028

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

11 in total

Review 1. Immunological effects of BRAF+MEK inhibition.

Authors: Paolo A Ascierto; Reinhard Dummer
Journal: Oncoimmunology Date: 2018-07-23 Impact factor: 8.110

2. Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib.

Authors: Annette Compter; Willem Boogerd; Johannes V van Thienen; Dieta Brandsma
Journal: Neurol Clin Pract Date: 2017-10

Review 3. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.

Authors: Kierstin Utter; Chloe Goldman; Sarah A Weiss; Richard L Shapiro; Russell S Berman; Melissa Ann Wilson; Anna C Pavlick; Iman Osman
Journal: Oncology Date: 2017-07-27 Impact factor: 2.935

4. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

Authors: Douglas B Johnson; Erika K Wallender; Daniel N Cohen; Sunaina S Likhari; Jeffrey P Zwerner; Jennifer G Powers; Lisa Shinn; Mark C Kelley; Richard W Joseph; Jeffrey A Sosman
Journal: Cancer Immunol Res Date: 2013-12 Impact factor: 11.151

Facial palsy as a side effect of vemurafenib treatment in patients with metastatic melanoma.

Review 1. Immunological effects of BRAF+MEK inhibition.

2. Acute polyneuropathy in a metastatic melanoma patient treated with vemurafenib and cobimetinib.

Review 3. Treatment Outcomes for Metastatic Melanoma of Unknown Primary in the New Era: A Single-Institution Study and Review of the Literature.

4. Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy.

5. Neurological complications of new chemotherapy agents.

Review 6. Ocular Toxicity of Targeted Anticancer Agents.

Review 7. Development of encorafenib for BRAF-mutated advanced melanoma.

Review 8. Novel Drugs and Combination Therapies for the Treatment of Metastatic Melanoma.

9. Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

10. Characteristics of adverse drug reactions in a vemurafenib early post-marketing phase vigilance study in Japan.